​

BioStem Technologies Stock (NASDAQ:BSEM)


RevenueFinancialsChartTranscripts

Previous Close

$2.64

52W Range

$2.25 - $8.40

50D Avg

$3.61

200D Avg

$4.40

Market Cap

$41.95M

Avg Vol (3M)

$124.14K

Beta

0.26

Div Yield

-

BSEM Company Profile


BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

73

IPO Date

Mar 17, 2015

Website

BSEM Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceJun 26
Hospital$6.71M
Other$88.56K

Fiscal year ends in Dec 25 | Currency in USD

BSEM Financial Summary


Dec 25Dec 24Dec 23
Revenue$47.48M$301.83M$16.69M
Operating Income$-689.15K$31.20M$-7.78M
Net Income$-6.58M$31.88M$-8.48M
EBITDA$-469.73K$31.49M$-7.55M
Basic EPS$-0.39$1.95$-0.62
Diluted EPS$-0.39$1.47$-0.62

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q2 26Aug 12, 26 | 4:30 PM
Q4 25Mar 24, 26 | 4:30 PM
Q3 25Nov 13, 25 | 4:30 PM